3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
3
Colorectal Neoplasms
3
Lymphoma
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Quality of Life
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Mixed Dementias
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Maxillary Sinus Neoplasms
1
Lymphoma, Follicular
1
Lewy Body Disease
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
aldesleukin
26
Sunitinib
25
Interferon-alpha
21
Everolimus
18
Sorafenib
16
Cyclophosphamide
16
Filgrastim
13
Bevacizumab
13
Nivolumab
11
Gemcitabine
11
Interleukin-2
10
Axitinib
10
fludarabine phosphate
9
Gene Expression Profiling
9
temsirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Doxorubicin
8
pembrolizumab
7
Radiotherapy
6
Radiosurgery
6
Polymerase Chain Reaction
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Ifosfamide
5
Fluorouracil
5
Erlotinib Hydrochloride
5
Capecitabine
5
Bortezomib
5
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Kidney Neoplasms
×
Referral and Consultation
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts